SIX Swiss Exchange · Financial Services
Invest in BB Biotech stock from India
Indian and foreign residents can buy BB Biotech (BION) shares directly through Paasa.
By Paasa · Updated
BB Biotech at a glance
- Price
- CHF 51.10-CHF 0.10 (0.20%)
- Market cap
- CHF 2.82B
- Day range
- CHF 50.90 – CHF 51.60
- P/E
- 2.09
- Dividend yield
- 4.40%
- Volume
- 66.72K
- 1 month
- -9.07%
- 6 months
- +18.01%
- YTD
- +17.88%
- 1 year
- +44.35%
- 5 years
- -41.67%
BB Biotech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 76.8M | CHF 111.6M | CHF 35.0K | CHF 4.0K | −CHF 396.2M |
| Gross profit | CHF 76.8M | CHF 111.6M | CHF 35.0K | CHF 4.0K | −CHF 396.2M |
| Operating income | CHF 586.8M | CHF 84.4M | −CHF 29.9M | −CHF 38.6M | −CHF 52.6M |
| Net income | CHF 578.1M | CHF 75.9M | −CHF 206.6M | −CHF 357.8M | −CHF 404.8M |
| Earnings per share | CHF 10.54 | CHF 1.38 | −CHF 3.77 | −CHF 6.50 | −CHF 7.31 |
| EBITDA | CHF 578.6M | CHF 80.3M | −CHF 34.6M | −CHF 43.0M | −CHF 59.2M |
| Total assets | CHF 2.8B | CHF 2.4B | CHF 2.6B | CHF 3.1B | CHF 3.6B |
| Total debt | CHF 0.0 | CHF 117.5M | CHF 304.9M | CHF 363.0M | CHF 355.0M |
| Cash and short-term investments | CHF 99.4M | CHF 2.4B | CHF 2.6B | CHF 3.1B | CHF 3.6B |
| Shareholders' equity | CHF 2.8B | CHF 2.3B | CHF 2.3B | CHF 2.7B | CHF 3.3B |
| Operating cash flow | CHF 309.1M | CHF 304.6M | CHF 218.3M | −CHF 357.8M | −CHF 94.8M |
| Free cash flow | CHF 309.1M | CHF 304.6M | CHF 218.3M | −CHF 357.8M | −CHF 94.8M |
| Capital expenditure | CHF 0.0 | CHF 0.0 | CHF 0.0 | CHF 0.0 | CHF 0.0 |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Tecan | TECN.SW | CHF 223.20 | CHF 2.82B |
| Idorsia | IDIA.SW | CHF 4.44 | CHF 1.17B |
| Basilea Pharmaceutica | BSLN.SW | CHF 68.70 | CHF 850.28M |
| Kuros Biosciences | KURN.SW | CHF 17.61 | CHF 694.53M |
| Santhera Pharmaceuticals | SANN.SW | CHF 15.22 | CHF 225.73M |
| Newron Pharmaceuticals | NWRN.SW | CHF 10.46 | CHF 217.63M |
| Molecular Partners | MOLN.SW | CHF 3.22 | CHF 120.79M |
| Relief Therapeutics | RLF.SW | CHF 2.89 | CHF 36.28M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in BB Biotech from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search BION and buy
Find BB Biotech by name or by its ticker, BION, and place your order.
Why invest in BB Biotech from India
What BB Biotech does
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. BB Biotech operates in the Asset Management industry within the Financial Services sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy BB Biotech stock from India?
Yes. Indian residents and NRIs can buy BB Biotech (BION) shares directly through Paasa. BB Biotech is listed on the SIX Swiss Exchange, in the Asset Management industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell BB Biotech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.